Naoclis

Naoclis is an emerging French biotechnology company specializing in Targeted Alpha Therapy (TAT), an innovative approach to cancer treatment using alpha-emitting radioisotopes. The company specifically focuses on Astatine-211 (211At), a rare and highly potent isotope that offers high linear energy transfer to destroy cancer cells while minimizing damage to surrounding healthy tissue. Headquartered in Nantes, France, Naoclis operates within a premier nuclear medicine ecosystem, maintaining close ties with the Arronax GIP (a high-energy cyclotron facility) and the University of Nantes. The company's mission is to develop a proprietary pipeline of astatinated radiopharmaceuticals and provide specialized expertise in astatination chemistry to the broader pharmaceutical industry.